Happy Monday. It’s Sept. 8, 2025. These are today’s top moving stocks, a segment of our daily live blog, Stock Market Today. To get updates on how the market is performing, as well as data and insights about the broader U.S. economy, click the link above to find today’s edition.
Planet Labs
Satellite imaging company Planet Labs (PL) (+39.7%) is today’s best-performing stock, hitting a 52-week high after reporting strong earnings, with revenue up 20%. The company also raised its outlook and, like seemingly all spacefaring firms these days, reported a record backlog.
TheStreet Pro’s Stephen Guilfoyle has a whole write-up about the company this afternoon, which was a one-time member of TheStreet’s “Stocks Under $10” portfolio. However, in light of today’s earnings, Guilfoyle simply said: “I want to own some of this small-cap stock.”
EchoStar
Staying on a satellite note, EchoStar (SATS) (+18%) is up today after announcing a deal to sell wireless spectrum to Elon Musk’s SpaceX as part of a $17 billion deal. The acquisition will help Musk’s Starlink satellite business expand its 5G offering, while the acquisition will also help Boost Mobile subscribers access satellite calls.
Shares of competitor Globalstar (GSAT) (+20%) were up on the sale, as more investors began to marinate on the value of wireless spectrum and price it into the value of various telecom names. Iridium Communications (IRDM) (-12.7%) and AST SpaceMobile ASTS (-5.7%) fell.
Robinhood
Robinhood (HOOD) (+14%) is up after scoring addition to one of Wall Street’s most exclusive clubs: the S&P 500. The brokerage will be flanked by adtech company AppLovin (APP) (+11%) and industrial firm Emcor Group (EME) (-0.36%).
Check out our Friday coverage on Robinhood and AppLovin’s big addition to the index, how they got in, and what companies could be next:
Related: These two popular tech stocks just got added to the S&P 500
Summit Therapeutics
Summit Therapeutics (SMMT) (-23.7%) purported to have a potential blockbuster on their hands when they began a trial of ivonescimab in advanced lung cancer. The drug, already approved in China, was floated as a possible competitor to the standard of care, Merck‘s (MRK) (-1%) Keytruda.
Those hopes might have been misplaced, as the company’s updated Phase III results in North America and Europe were shown to be weaker than in China. Tumor progression fell just 33% in western markets, compared with the 45% measured in China.
The revelation follows already-disappointing results from the original trial’s release in May, which showed the drug missed its overall survival endpoint; instead, just meeting the disease-free progression endpoint of the Phase III study.
The results have thrown a wrench in the likelihood of the drug’s approval by regulators in the U.S. and Europe.
BioNTech
BioNTech (BNTX) (-8.5%) is having some more luck in the lab as of late than the aforementioned Summit, but that doesn’t mean investors are seeing the value.
Friday, BioNTech announced that a new breast cancer drug candidate had exceeded expectations, even surpassing Roche’s standard of care therapy, Kadcyla. This morning, the firm released results showing their updated Covid-19 vaccine with American pharmaceutical giant Pfizer (PFE) (-1.7%) had an increased immune response in a trial. And finally, it released data from a global study of its new small cell lung cancer drug with Bristol Myers Squibb.
Still, the stock is down today; closely-situated rival Moderna (MRNA) (-3.5%) is also down.
CVS Health
CVS Health (CVS) (-4.6%), the parent company of Aetna, fell after management failed to offer an update on the rating of the company’s Medicare Advantage plans.
The carefully-watched quality ratings, also known as Stars, are a critical measure in what compensation health care providers receive for government plans. The Stars are based off of factors such as customer service, member experience, and quality of care.
Last year, 88% of Aetna’s Medicare Advantage plans were rated 4 stars or greater, marking the “highest-ever Aetna member experience score.”